Foghorn Therapeutics Inc.

General Information

The chromatin regulatory system orchestrates gene expression–the turning on and off of genes–which is fundamental to how all our cells function. Breakdowns in this system lead to a wide range of diseases impacting millions of patients. Understanding the mechanism of how this system works could lead to an entirely new class of therapeutics. To our knowledge, we are the only company with the ability to study the chromatin regulatory system at scale, in context, and in an integrated way.

We are pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system. Breakdowns in the chromatin regulatory system are associated with over 50 percent of all cancers. Addressing these breakdowns could potentially provide therapies for over 2.5 million patients. Consequently we are initially focused in oncology.

We are developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors, for which we plan to file INDs in the fourth quarter of 2020 and in the first half of 2021, respectively. Our product candidates are in preclinical development, and so we currently do not have any products approved for commercial sale. Our vision is to use our Gene Traffic Control platform to discover and develop drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology.

Industry: Pharmaceuticals
Employees: 85
Founded: 2015
Contact Information
Address 500 Technology Square, Ste 700 Cambridge MA 02139
Phone Number 617-586-3100
Web Address
View Prospectus: Foghorn Therapeutics Inc.
Financial Information
Market Cap $571.04mil
Revenues $0 mil (last 12 months)
Net Income $-58.1 mil (last 12 months)
IPO Profile
Symbol FHTX
Exchange NASDAQ
Shares (millions): 7.5
Price range $16.00 - $16.00
Est. $ Volume $120.0 mil
Manager / Joint Managers Goldman Sachs/ Morgan Stanley/ Cowen and Company
CO-Managers Wedbush Securities
Expected To Trade: 10/23/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change